Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – X-ray contrast imaging agent
Reexamination Certificate
2005-03-29
2005-03-29
Jones, Dameron L. (Department: 1616)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
X-ray contrast imaging agent
C424S001110, C424S001810, C424S001850, C424S009100, C424S001890
Reexamination Certificate
active
06872381
ABSTRACT:
This invention is directed to the use of radiopharmaceuticals in diagnosing Alzheimer's disease. In particular the radiopharmaceuticals of the invention are able to pass through the blood-brain barrier and bind to the CCR1 receptor present in brain tissue of patients having Alzheimer's disease.
REFERENCES:
patent: 5286728 (1994-02-01), Ferrini
patent: 5358712 (1994-10-01), Efange et al.
patent: 5721243 (1998-02-01), Efange et al.
patent: 5919797 (1999-07-01), Goodman et al.
patent: 6207665 (2001-03-01), Bauman et al.
patent: 6676926 (2004-01-01), Hilger et al.
patent: 2 758 328 (1998-07-01), None
patent: WO 9216239 (1992-10-01), None
patent: WO 9601656 (1996-01-01), None
patent: WO 9802151 (1998-01-01), None
patent: WO 9951594 (1999-10-01), None
patent: WO 0014086 (2000-03-01), None
patent: WO 0042011 (2000-07-01), None
patent: WO 0058305 (2000-10-01), None
K. Bergström et al., “Iodine-123 labelled Z-(R,R)-IQNP: a potential radioligand for visualization of M1and M2muscarinic acetylcholine receptors in Alzheimer's disease”, European Journal of Nuclear Medicine, vol. 26, No. 11, pp. 1482-1485, Nov. 1999, XP-002193046.
S. Oya et al., “Small and neutral TcvO.BAT, bisaminoethanethiol (N2S2) complexes for developing new brain imaging agents”, Nuclear Medicine & Biology, vol. 25, pp. 35-140, 1998.
A. Fischman et al., “Rapid detection of parkinson's disease by SPECT with altropane: A selective ligand for dopamine transporters”, SYNAPSE, vol. 29, pp. 128-141, 1998.
J. Logan et al., “Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects”, Journal of Cerebral Blood Flow and metabolism, vol. 10, pp. 740-747, 1990.
J. Seibyl et al., “Iodine-123-β-CIT an diodine-123-FPCIT SPECT measurement of dopamine transporter in healthy subjects and parkinson's patients”, The Journal of Nuclear Medicine, vol. 39, No. 9, pp. 1500-1508, Sep. 1998.
M. Melloul et al., “Double-Phase99mTc-sestamibi scintimammography and trans-scan in diagnosing breast cancer”, The Journal Of Nuclear Medicine, vol. 40, No. 3, pp. 380, Mar. 1999.
J.L. Moretti et al., “Comparison of brain SPECT using99mTc-Bicisate (L,L-ECD) and [123I]IMP in cortical and subcortical strokes”, Journal Of Cerebral Blood Flow And Metabolism, vol. 14 (Suppl. 1), pp. S84-S90, 1994.
J.M. Links, “Visual Interpretation,” Chapter 22 in HN Wagner et al. (Eds.), Principles of Nuclear Medicine, W.B. Saunders Company, 2ndEdition, 1995, pp. 391-392.
EL Palmer et al. (Eds.), Practical Nuclear Medicine, Chapter 3 “Cardiovascular Imaging,” W.B. Saunders Company, 1992, pp. 71-120.
Dinter Harald
Halks-Miller Meredith
Hesselgesser Joseph E.
Hilger Christoph-Stephan
Horuk Richard
Jones Dameron L.
Millen White Zelano & Branigan P.C.
Schering AG
LandOfFree
Radiopharmaceuticals for diagnosing Alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Radiopharmaceuticals for diagnosing Alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiopharmaceuticals for diagnosing Alzheimer's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3420278